Darrell Plumage, MD
Internal Medicine · Pierre, SDNPI 1013938844
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 409 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 12.6% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in SD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 409 payments — averaging $14.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$730
- Pfizer$680
- Amgen$667
- Novo Nordisk$592
- E.r. Squibb & Sons, L.L.C.$501
- GSK$374
- plus $2K from 22 others
What the payments were for
- Consulting fees$601%
- Food & beverage$5,70599%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 45 | $730 |
| Pfizer | 47 | $680 |
| Amgen | 49 | $667 |
| Novo Nordisk | 42 | $592 |
| E.r. Squibb & Sons, L.L.C. | 39 | $501 |
| GSK | 45 | $374 |
| Johnson & Johnson | 37 | $342 |
| Boehringer Ingelheim | 22 | $303 |
| Astellas Pharma US Inc | 18 | $286 |
| Daiichi Sankyo Inc. | 9 | $185 |
| Novartis | 8 | $154 |
| Medtronic | 2 | $113 |
| Exact Sciences | 7 | $111 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $99 |
| AstraZeneca(2 entities) | 6 | $95 |
| Vertex | 6 | $95 |
| Sanofi-aventis U.S. LLC | 3 | $91 |
| AbbVie | 3 | $63 |
| Mylan Specialty L.p. | 3 | $58 |
| Bayer | 2 | $41 |
| Philips North America LLC | 2 | $38 |
| Grifols USA, LLC | 2 | $35 |
| Merck | 2 | $31 |
| Boston Scientific | 1 | $31 |
| Inspire Medical Systems, Inc. | 1 | $20 |
| Dexcom, Inc. | 1 | $18 |
| Actelion Pharmaceuticals US, Inc. | 1 | $14 |
| Solventum Corporation | 1 | $14 |
How this compares
$5,779 in reported general payments places this provider in the 95th percentile of 178 internal medicine providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 298 | $207,721 |
| OzempicSemaglutide | 147 | $143,237 |
| IngrezzaValbenazine Tosylate | 18 | $96,838 |
| JardianceEmpagliflozin | 143 | $82,393 |
| MounjaroTirzepatide | 51 | $65,170 |
| NuplazidPimavanserin Tartrate | 26 | $64,974 |
| XareltoRivaroxaban | 89 | $57,026 |
| MyrbetriqMirabegron | 98 | $41,981 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 54 | $39,511 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 82 | $27,659 |
| Invega SustennaPaliperidone Palmitate | 15 | $27,439 |
| FarxigaDapagliflozin Propanediol | 50 | $24,762 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 30 | $17,247 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $14,642 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 18 | $13,584 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $680 | $215,790324 claims |
| Novo NordiskOzempic | $592 | $143,237147 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $303 | $99,640173 claims |
| Johnson & JohnsonXarelto, Invega Sustenna | $342 | $84,465104 claims |
| Lilly USA, LLCMounjaro | $730 | $65,17051 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta | $374 | $55,18391 claims |
| Astellas Pharma US IncMyrbetriq | $286 | $41,98198 claims |
| AstraZenecaFarxiga | $95 | $24,76250 claims |
| AbbVieCreon | $63 | $11,02620 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 178 internal medicine providers in South Dakota.
Other internal medicine in Pierre
- Robert AllisonPierre$6K
- Philip MeyerPierre$289
- Jennifer MayRapid City$52K
- Richard BeasleyRapid City$25K
- Issam TurkRapid City$14K
- Janell PowellSioux Falls$7K
- Maaz BadshahSioux Falls$6K
- Travis HendersonMobridge$6K
- Wendy VetterSioux Falls$5K
- Josh HendersonMobridge$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.